Cost For Biologics A Hurdle Too High In China? Think Again
This article was originally published in Scrip
Executive Summary
Even in China where patients pay out-of-pocket for high-priced innovative treatments such as cancer therapies and biologics, drug costs are not the only factor influencing patients and doctors, notes a new study by Johnson & Johnson.